Immune system modulation targets (ISMTs)

Immune system modulation targets represent a broad and heterogeneous category of molecular structures—including receptors, enzymes, and cytokines—that are pharmacologically manipulated to regulate the immune response [Source: PubMed - PMID 30205096]. These targets are central to modern oncology, where checkpoint inhibitors like PD-1 and CTLA-4 are used to overcome tumor-induced immunosuppression, and to rheumatology, where TNF-alpha and interleukin receptors are targeted to mitigate chronic inflammation [Source: Nature Reviews Drug Discovery]. By modulating these pathways, therapeutics can either amplify a patient’s defense against pathogens and malignant cells or dampen pathological immune activity in autoimmune conditions [Source: NIH - NIAID]. Because these targets often control systemic signaling networks, their therapeutic engagement requires a delicate balance to avoid severe toxicity, such as cytokine storms or systemic autoimmunity [Source: StatPearls - Immunotherapy]. This entry is considered 'incorrect' as a single target because it encompasses an entire functional class rather than a specific protein or receptor subunit.

Other names

Immunomodulatory targetsImmune checkpointsImmunotherapeutic targetsImmunosuppressive targetsImmune stimulatory targets

Drugs targeting these entities work through diverse mechanisms including immune checkpoint blockade (e.g., PD-1/CTLA-4 inhibition), cytokine neutralization (e.g., TNF-alpha or IL-6 antagonism), T-cell activation/co-stimulation, and modulation of E3 ubiquitin ligase activity (e.g., CRBN modulation) [Source: NIH/StatPearls - Immunomodulators].